58 Hepatocellular carcinoma remains one of the most common and difficult-to-treat forms of liver cancer worldwide, with limited therapeutic options and frequent resistance to existing treatments driving the search for new targeted approaches. A study published in Genes & Diseases by researchers from the China Academy of Chinese Medical Sciences and Fujian University of Traditional Chinese Medicine has now detailed how the antimalarial drug artesunate, a derivative of artemisinin, exerts anticancer effects against this malignancy. Earlier work by the same team had identified glucosylceramidase (GBA) as a direct molecular target of artesunate. The new research builds on that finding, providing the structural and mechanistic detail of the interaction and explaining the downstream processes that lead to tumour cell death. The investigators combined computational modelling, biochemical tests, cellular experiments, and animal studies. Artesunate strongly reduced the proliferation of hepatocellular carcinoma cells and increased apoptosis, with HepG2 cells proving more sensitive to the drug than MHCC-97H cells. These effects were linked to disruption of sphingolipid balance, build-up of glucosylceramide-related metabolites, mitochondrial dysfunction, and activation of caspase-dependent apoptotic pathways. Network analysis and laboratory validation pointed to a specific signalling cascade, the GBA–ceramide–CTSD–α-syn–BID–BAX axis. By inhibiting GBA, artesunate interferes with ceramide metabolism, which impairs the maturation of cathepsin D (CTSD) and leads to the accumulation of α-synuclein. The accumulated α-synuclein then promotes mitochondrial apoptosis through cleavage of BID and upregulation of BAX, triggering caspase activation. Experiments in which ceramide was supplemented or α-synuclein was inhibited confirmed that this pathway is central to the drug’s ability to kill cancer cells. Structural studies identified three amino acid residues inside the GBA active site as critical for artesunate binding: Y313, E340, and N396. When researchers introduced mutations, especially E340R and N396R, binding of artesunate was markedly reduced and GBA enzymatic activity declined, causing the drug to lose its capacity to control the downstream apoptotic signals. This established a direct connection between engagement of the target and the observed therapeutic activity. The findings position GBA as a promising therapeutic target and support the rational design of future GBA-directed treatments for this cancer. Although the proposed mechanism was confirmed in hepatocellular carcinoma cell lines and backed by in vivo experiments, the authors note that further testing in patient-derived organoids and xenograft models, together with thorough long-term safety evaluations, will be required before clinical translation can be considered. Artesunate has already shown activity against several cancers in laboratory settings, and its established safety profile as an antimalarial may accelerate development if the GBA-related pathway proves robust in additional models. The study adds a concrete molecular rationale for exploring artesunate, or new compounds that mimic its interaction with GBA, as a potential option for patients with limited treatment choices in hepatocellular carcinoma, and underscores the value of examining existing medicines for new indications.